CEO's open-market purchase at $11.12 signals strong insider conviction ahead of potential upcoming catalysts (pipeline data, regulatory milestones). Monitor for additional insider buying or pipeline announcements in the coming weeks.
KURA drugs
KURA drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 18 $12.33entry
- T+1 · 3mo ago +1.62%α +1.41% · $12.53
- T+5 · 3mo ago +10.22%α +10.42% · $13.59
- T+20 · 2mo ago −7.83%α −6.84% · $11.37
- T+60 · 6d ago −38.60%α −36.56% · $7.57
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kura Oncology CEO Troy Wilson purchased 100,000 shares worth $1.11M on the open market at $11.12/share, representing a material insider conviction buy. This is a strong standalone bullish signal from the highest-ranking insider, particularly notable given the company's $966M market cap and the CEO's direct cash deployment.
Key Financial Metrics
Key Facts
- CEO Troy Wilson purchased 100,000 shares at $11.12/share for total consideration of $1,112,000
- Purchase represents approximately 0.12% of KURA's $966M market cap
- This is the only insider trade in the past 7 days and the only buy in the past 30 days
- CEO is the highest-ranking insider, making this a conviction buy signal
Financial Impact
CEO invested $1.11M of personal capital at $11.12/share, representing ~0.12% of market cap
Risk Factors
- Single insider trade may not reflect broader company outlook
- Biotech sector volatility could overshadow insider signal
- No specific catalyst disclosed alongside the purchase
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| INSIDER-BUY Data (Synthetic) | 0001193125-26-354201 |
Track record
29 reports on KURA
6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 9 of 13 went positive at some point.
Filters
- Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
- Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
- Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers